Figure 4.

Change in ratio of agalactosylated to monogalactosylated N-glycans in serum (sG0/G1) with therapy does not distinguish methotrexate (MTX) and TNF inhibition. Relationship between therapy and the correlation between clinical improvement and changes in sG0/G1 for patients in whom MTX or TNF inhibition was the only new therapeutic agent in the interval between t = 0 and t = 3 months. TNF inhibitor (n = 79) (Autoimmune Biomarkers Collaborative Network and Nested I), Spearman's ρ = 0.34; MTX (n = 19) (Nested I only), Spearman's ρ = 0.16 (P = 0.56 vs TNF inhibitor group).

Ercan et al. Arthritis Research & Therapy 2012 14:R43   doi:10.1186/ar3756
Download authors' original image